{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:45:50Z","timestamp":1764791150605,"version":"3.46.0"},"reference-count":40,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Undifferentiated pleomorphic sarcoma (UPS) of soft tissue is defined as a sarcoma with no recognizable line of differentiation. During the past few decades, advances in ancillary studies and review of prior UPS diagnoses have narrowed the category of UPS by excluding more-specific malignancies. However, few of those studies have specifically targeted pleomorphic hematolymphoid neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To determine what fraction of UPS cases are misclassified pleomorphic hematolymphoid neoplasms, such as anaplastic large cell lymphoma, diffuse large B-cell lymphoma, histiocytic sarcoma (HS), myeloid sarcoma, and follicular dendritic cell sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Sixty-one UPS cases were screened by tissue microarray and an immunostain panel with subsequent analysis on whole block sections for suspicious cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Five of 61 tumors (8%) were suggestive of HS based on the screening panel and were further evaluated with additional immunostains (PU.1, CD45, CD163) using whole sections. The 5 candidate HS cases were only focally positive for at most one stain with most staining in smaller, less-pleomorphic cells. Ultimately, no UPS met criteria for anaplastic large cell lymphoma, diffuse large B-cell lymphoma, myeloid sarcoma, follicular dendritic cell sarcoma, or HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Our results suggest that a UPS of somatic soft tissue is unlikely to represent a misclassified hematopoietic malignancy. Exclusion of HS is most challenging, but immunostaining for PU.1, a nuclear transcription factor, may be easier to interpret in this context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0580-oa","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T09:46:06Z","timestamp":1584092766000},"page":"1547-1552","source":"Crossref","is-referenced-by-count":4,"title":["Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue"],"prefix":"10.5858","volume":"144","author":[{"given":"John","family":"Cannatella","sequence":"first","affiliation":[{"name":"From the Department of Pathology (Cannatella, Horvai), University of California, San Francisco, San Francisco"},{"name":"Cannatella is now with the Department of Pathology, University of Arkansas for Medical Sciences, Little Rock."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ganapathi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine (Ganapathi), University of California, San Francisco, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Horvai","sequence":"additional","affiliation":[{"name":"From the Department of Pathology (Cannatella, Horvai), University of California, San Francisco, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"unstructured":"Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone . 4th ed.Lyon, France; IARC Press; 2013. World Health Organization Classification of Tumors, vol5.","key":"2020112514203379500_i1543-2165-144-12-1547-b01"},{"doi-asserted-by":"crossref","unstructured":"Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century. Expert Rev Anticancer Ther. 2009;9(8):1135\u20131144.","key":"2020112514203379500_i1543-2165-144-12-1547-b02","DOI":"10.1586\/era.09.76"},{"doi-asserted-by":"crossref","unstructured":"Fletcher CD . Pleomorphic malignant fibrous histiocytoma: fact or fiction?\u2014a critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16(3):213\u2013228.","key":"2020112514203379500_i1543-2165-144-12-1547-b03","DOI":"10.1097\/00000478-199203000-00001"},{"doi-asserted-by":"crossref","unstructured":"Fletcher CD, Gustafson P, Rydholm A, Will\u00e9n H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19(12):3045\u20133050.","key":"2020112514203379500_i1543-2165-144-12-1547-b04","DOI":"10.1200\/JCO.2001.19.12.3045"},{"doi-asserted-by":"crossref","unstructured":"Lawson CW, Fisher C, Gatter KC . An immunohistochemical study of differentiation in malignant fibrous histiocytoma. Histopathology. 1987;11(4):375\u2013383.","key":"2020112514203379500_i1543-2165-144-12-1547-b05","DOI":"10.1111\/j.1365-2559.1987.tb02642.x"},{"doi-asserted-by":"crossref","unstructured":"Oda Y, Tamiya S, Oshiro Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595\u2013606.","key":"2020112514203379500_i1543-2165-144-12-1547-b06","DOI":"10.1046\/j.1440-1827.2002.01399.x"},{"unstructured":"Khalidi HS, Singleton TP, Weiss SW . Inflammatory malignant fibrous histiocytoma: distinction from Hodgkin's disease and non-Hodgkin's lymphoma by a panel of leukocyte markers. Mod Pathol. 1997;10(5):438\u2013442.","key":"2020112514203379500_i1543-2165-144-12-1547-b07"},{"doi-asserted-by":"crossref","unstructured":"Goldblum JR . An approach to pleomorphic sarcomas: can we subclassify, and does it matter? Mod Pathol . 2014;27(suppl 1):S39\u2013S46.","key":"2020112514203379500_i1543-2165-144-12-1547-b08","DOI":"10.1038\/modpathol.2013.174"},{"doi-asserted-by":"crossref","unstructured":"Hornick JL . Subclassification of pleomorphic sarcomas: how and why should we care? Ann Diagn Pathol . 2018;37: 118\u2013124.","key":"2020112514203379500_i1543-2165-144-12-1547-b09","DOI":"10.1016\/j.anndiagpath.2018.10.006"},{"doi-asserted-by":"crossref","unstructured":"Carvalho SD, Pissaloux D, Cromb\u00e9 A, Coindre JM, Le Loarer F. Pleomorphic sarcomas: the state of the art. Surg Pathol Clin. 2019;12(1):63\u2013105.","key":"2020112514203379500_i1543-2165-144-12-1547-b10","DOI":"10.1016\/j.path.2018.10.004"},{"doi-asserted-by":"crossref","unstructured":"Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u2013181.","key":"2020112514203379500_i1543-2165-144-12-1547-b11","DOI":"10.1182\/blood-2017-07-793984"},{"unstructured":"von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018. J Natl Compr Cancer Netw. 2018;16(5):536\u2013563.","key":"2020112514203379500_i1543-2165-144-12-1547-b12"},{"doi-asserted-by":"crossref","unstructured":"Horvai AE, Kramer MJ, O'Donnell R. \u03b2-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 2006;130(6):792\u2013798.","key":"2020112514203379500_i1543-2165-144-12-1547-b13","DOI":"10.5858\/2006-130-792-CNECWC"},{"unstructured":"Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon, France: IARC Press;2017. World Health Organization Classification of Tumours; vol 2.","key":"2020112514203379500_i1543-2165-144-12-1547-b14"},{"unstructured":"Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber DA . Hematopathology. 1st ed. St Louis, Missouri: Elsevier;2011.","key":"2020112514203379500_i1543-2165-144-12-1547-b15"},{"doi-asserted-by":"crossref","unstructured":"Shanmugam V, Griffin GK, Jacobsen ED, Fletcher CDM, Sholl LM, Hornick JL . Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol. 2019;32(6):830\u2013843.","key":"2020112514203379500_i1543-2165-144-12-1547-b16","DOI":"10.1038\/s41379-018-0200-x"},{"doi-asserted-by":"crossref","unstructured":"McCune RC, Syrbu SI, Vasef MA . Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006;19(7):1010\u20131018.","key":"2020112514203379500_i1543-2165-144-12-1547-b17","DOI":"10.1038\/modpathol.3800622"},{"doi-asserted-by":"crossref","unstructured":"Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol. 2003;162(1):243\u2013253.","key":"2020112514203379500_i1543-2165-144-12-1547-b18","DOI":"10.1016\/S0002-9440(10)63815-1"},{"doi-asserted-by":"crossref","unstructured":"Gualco G, Natkunam Y, Bacchi CE . The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases. Mod Pathol. 2012;25(5):661\u2013674.","key":"2020112514203379500_i1543-2165-144-12-1547-b19","DOI":"10.1038\/modpathol.2011.200"},{"doi-asserted-by":"crossref","unstructured":"Huang SC, Chang CL, Huang CH, Chang CCJ . Histiocytic sarcoma\u2014a case with evenly distributed multinucleated giant cells. Pathol Res Pract. 2007;203(9):683\u2013689.","key":"2020112514203379500_i1543-2165-144-12-1547-b20","DOI":"10.1016\/j.prp.2007.05.013"},{"doi-asserted-by":"crossref","unstructured":"Chan JKC . Proliferative lesions of follicular dendritic cells: an overview, including a detailed account of follicular dendritic cell sarcoma, a neoplasm with many faces and uncommon etiologic associations. Adv Anat Pathol. 1997;4(6):387\u2013411.","key":"2020112514203379500_i1543-2165-144-12-1547-b21","DOI":"10.1097\/00125480-199711000-00048"},{"doi-asserted-by":"crossref","unstructured":"al Saati T, Tkaczuk J, Krissansen G, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91(6):2076\u20132084.","key":"2020112514203379500_i1543-2165-144-12-1547-b22","DOI":"10.1182\/blood.V91.6.2076"},{"doi-asserted-by":"crossref","unstructured":"Chan JKC, Buchanan R, Fletcher CD . Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol. 1990;14(10):983\u2013988.","key":"2020112514203379500_i1543-2165-144-12-1547-b23","DOI":"10.1097\/00000478-199010000-00013"},{"doi-asserted-by":"crossref","unstructured":"Pan Z, Hu S, Li M, et al. ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature. Am J Surg Pathol. 2017;41(1):25\u201338.","key":"2020112514203379500_i1543-2165-144-12-1547-b24","DOI":"10.1097\/PAS.0000000000000753"},{"doi-asserted-by":"crossref","unstructured":"Haralambieva E, Pulford KAF, Lamant L, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B- cell lymphomas. Br J Haematol. 2000;109(3):584\u2013591.","key":"2020112514203379500_i1543-2165-144-12-1547-b25","DOI":"10.1046\/j.1365-2141.2000.02045.x"},{"doi-asserted-by":"crossref","unstructured":"Obiorah IE, Ozdemirli M. Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass. Hematol Oncol Stem Cell Ther. 2018;11(3):178\u2013182.","key":"2020112514203379500_i1543-2165-144-12-1547-b26","DOI":"10.1016\/j.hemonc.2018.03.001"},{"doi-asserted-by":"crossref","unstructured":"Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+\/Ki-1+ with a high content of reactive histiocytes). Histopathology. 1990;16(4):383\u2013391.","key":"2020112514203379500_i1543-2165-144-12-1547-b27","DOI":"10.1111\/j.1365-2559.1990.tb01143.x"},{"doi-asserted-by":"crossref","unstructured":"Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433\u20135439.","key":"2020112514203379500_i1543-2165-144-12-1547-b28","DOI":"10.1182\/blood-2007-11-124792"},{"doi-asserted-by":"crossref","unstructured":"Brunner P, Rufle A, Dirnhofer S, et al. Follicular lymphoma transformation into histiocytic sarcoma: indications for a common neoplastic progenitor. Leukemia. 2014;28(9):1937\u20131940.","key":"2020112514203379500_i1543-2165-144-12-1547-b29","DOI":"10.1038\/leu.2014.167"},{"doi-asserted-by":"crossref","unstructured":"Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261\u2013272.","key":"2020112514203379500_i1543-2165-144-12-1547-b30","DOI":"10.1111\/his.12416"},{"doi-asserted-by":"crossref","unstructured":"Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014;21(4):290\u2013300.","key":"2020112514203379500_i1543-2165-144-12-1547-b31","DOI":"10.1177\/107327481402100405"},{"doi-asserted-by":"crossref","unstructured":"Rezk SA, Nathwani BN, Zhao X, Weiss LM . Follicular dendritic cells: origin, function, and different disease-associated patterns. Hum Pathol. 2013;44(6):937\u2013950.","key":"2020112514203379500_i1543-2165-144-12-1547-b32","DOI":"10.1016\/j.humpath.2012.10.005"},{"doi-asserted-by":"crossref","unstructured":"Fletcher AL, Acton SE, Knoblich K. Lymph node fibroblastic reticular cells in health and disease. Nat Rev Immunol. 2015;15(6):350\u2013361.","key":"2020112514203379500_i1543-2165-144-12-1547-b33","DOI":"10.1038\/nri3846"},{"doi-asserted-by":"crossref","unstructured":"Kurotaki D, Sasaki H, Tamura T. Transcriptional control of monocyte and macrophage development. Int Immunol. 2017;29(3):97\u2013107.","key":"2020112514203379500_i1543-2165-144-12-1547-b34","DOI":"10.1093\/intimm\/dxx016"},{"doi-asserted-by":"crossref","unstructured":"Mak KS, Funnell AP, Pearson RC, Crossley M. PU.1 and Haematopoietic Cell Fate: Dosage Matters. Int J Cell Biol. 2011;2011: 808524.","key":"2020112514203379500_i1543-2165-144-12-1547-b35","DOI":"10.1155\/2011\/808524"},{"doi-asserted-by":"crossref","unstructured":"Kwon OH, Lee CK, Lee YI, Paik SG, Lee HJ . The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. Biochem Biophys Res Commun. 2005;335(2):437\u2013446.","key":"2020112514203379500_i1543-2165-144-12-1547-b36","DOI":"10.1016\/j.bbrc.2005.07.092"},{"doi-asserted-by":"crossref","unstructured":"Chopin M, Seillet C, Chevrier S, et al. Langerhans cells are generated by two distinct PU.1-dependent transcriptional networks. J Exp Med. 2013;210(13):2967\u20132980.","key":"2020112514203379500_i1543-2165-144-12-1547-b37","DOI":"10.1084\/jem.20130930"},{"doi-asserted-by":"crossref","unstructured":"Belz GT, Nutt SL . Transcriptional programming of the dendritic cell network [published correction appears in Nat Rev Immunol. 2013;13(2):149]. Nat Rev Immunol. 2012; 12 (2):101\u2013113.","key":"2020112514203379500_i1543-2165-144-12-1547-b38","DOI":"10.1038\/nri3149"},{"doi-asserted-by":"crossref","unstructured":"Hung YP, Lovitch SB, Qian X. Histiocytic sarcoma: new insights into FNA cytomorphology and molecular characteristics. Cancer Cytopathol. 2017;125(8):604\u2013614.","key":"2020112514203379500_i1543-2165-144-12-1547-b39","DOI":"10.1002\/cncy.21851"},{"doi-asserted-by":"crossref","unstructured":"Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS . Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18(5):693\u2013704.","key":"2020112514203379500_i1543-2165-144-12-1547-b40","DOI":"10.1038\/modpathol.3800346"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/12\/1547\/2668799\/i1543-2165-144-12-1547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/12\/1547\/2668799\/i1543-2165-144-12-1547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:38Z","timestamp":1764790598000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/12\/article-p1547.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,3,13]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0580-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2020,3,13]]}}}